[go: up one dir, main page]

WO2013030670A3 - Tissue targeted fusobacterium antigenic activation of the immune response to treat intestinal cancers - Google Patents

Tissue targeted fusobacterium antigenic activation of the immune response to treat intestinal cancers Download PDF

Info

Publication number
WO2013030670A3
WO2013030670A3 PCT/IB2012/002065 IB2012002065W WO2013030670A3 WO 2013030670 A3 WO2013030670 A3 WO 2013030670A3 IB 2012002065 W IB2012002065 W IB 2012002065W WO 2013030670 A3 WO2013030670 A3 WO 2013030670A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusobacterium
immune response
tissue targeted
intestinal cancers
treat intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2012/002065
Other languages
French (fr)
Other versions
WO2013030670A2 (en
Inventor
Harold David Gunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qu Biologics Inc
Original Assignee
Qu Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qu Biologics Inc filed Critical Qu Biologics Inc
Publication of WO2013030670A2 publication Critical patent/WO2013030670A2/en
Publication of WO2013030670A3 publication Critical patent/WO2013030670A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/114—Fusobacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Aspects of the invention include methods of treating intestinal, e.g., lower intestinal such as colon and/or rectal, cancers by administering a composition that is antigenically specific for a Fusobacterium, such as Fusobacterium nucleatum.
PCT/IB2012/002065 2011-08-29 2012-08-24 Tissue targeted fusobacterium antigenic activation of the immune response to treat intestinal cancers Ceased WO2013030670A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528707P 2011-08-29 2011-08-29
US61/528,707 2011-08-29

Publications (2)

Publication Number Publication Date
WO2013030670A2 WO2013030670A2 (en) 2013-03-07
WO2013030670A3 true WO2013030670A3 (en) 2013-08-15

Family

ID=47756982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/002065 Ceased WO2013030670A2 (en) 2011-08-29 2012-08-24 Tissue targeted fusobacterium antigenic activation of the immune response to treat intestinal cancers

Country Status (1)

Country Link
WO (1) WO2013030670A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11226340B2 (en) 2016-04-26 2022-01-18 Qu Biologics Inc. Therapeutically triggering an innate immune response in a target tissue

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024103187A1 (en) * 2022-11-18 2024-05-23 Provincial Health Services Authority Fap2-derived antibodies and vaccines against fusobacterium

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074816A1 (en) * 2004-06-07 2009-03-19 Harold David Gunn Tissue targeted antigenic activation of the immune response to cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074816A1 (en) * 2004-06-07 2009-03-19 Harold David Gunn Tissue targeted antigenic activation of the immune response to cancers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CASTELLARIN ET AL.: "Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma", GENOME RESEARCH, vol. 22, February 2012 (2012-02-01), pages 299 - 306, XP055080533 *
CHEN ET AL.: "Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer, art e39743", PLOS ONE, vol. 7, June 2012 (2012-06-01), pages 1 - 9, XP003031297 *
KOSTIC ET AL.: "Genomic analysis identifies association of Fusobacterium with colorectal carcinoma", GENOME RESEARCH, vol. 22, February 2012 (2012-02-01), pages 292 - 298, XP055080536 *
RAY: "Fusobacterium nucleatum found in colon cancer tissue - could an infection cause colorectal cancer", NATURE REVIEWS GASTROENTEROLOGY AND HEPATOLOGY, vol. 8, December 2011 (2011-12-01), pages 662, XP008167269, DOI: doi:10.1038/nrgastro.2011.208 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11226340B2 (en) 2016-04-26 2022-01-18 Qu Biologics Inc. Therapeutically triggering an innate immune response in a target tissue

Also Published As

Publication number Publication date
WO2013030670A2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
PH12019502018A1 (en) Compositions, formulations and methods for treating ocular diseases
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
ECSP14017269A (en) COMPOUNDS TO TREAT SPINAL MUSCULAR ATROPHY
MY176489A (en) Novel tricyclic compounds as anticancer agents
HK1214815A1 (en) Enhancer of zeste homolog 2 inhibitors
EA201490423A1 (en) METHODS AND COMPOSITIONS RELATED TO p62 FOR TREATMENT AND PREVENTION OF CANCER
BR112014021104A2 (en) methods and compositions for the treatment of huntington's disease
MX2016002544A (en) Compounds useful as immunomodulators.
MX2015007916A (en) Peri-carbinols.
MX2014012266A (en) Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents.
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MY164354A (en) Asymmetric ureas and medical uses thereof
MX2016014559A (en) Compounds for treatment of cancer.
PH12016501968A1 (en) Novel macrocyclic compounds
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
HK1206331A1 (en) Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways
PH12013501018A1 (en) 177lutetium-labeled bombesin analogs for radiotherapy
MX2015005733A (en) Tricyclic compounds for use in the treatment and/or control of obesity.
SA515360377B1 (en) Somatostatin-dopamine chimeric analogs
WO2013030670A3 (en) Tissue targeted fusobacterium antigenic activation of the immune response to treat intestinal cancers
NZ610547A (en) Novel monensin derivatives for the treatment and prevention of protozoal infections
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
GB201206984D0 (en) New therapeutic use
WO2013103792A3 (en) Method of treating cancer by administration of low levels of heat shock protein 70 (hsp70)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12827765

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12827765

Country of ref document: EP

Kind code of ref document: A2